» Articles » PMID: 23280477

Antibodies to Contactin-1 in Chronic Inflammatory Demyelinating Polyneuropathy

Overview
Journal Ann Neurol
Specialty Neurology
Date 2013 Jan 3
PMID 23280477
Citations 129
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a frequent autoimmune neuropathy with a heterogeneous clinical spectrum. Clinical and experimental evidence suggests that autoantibodies may be involved in its pathogenesis, but the target antigens are unknown. Axoglial junction proteins have been proposed as candidate antigens. We examined the reactivity of CIDP patients' sera against neuronal antigens and used immunoprecipitation for antigen unraveling.

Methods: Primary cultures of hippocampal neurons were used to select patients' sera that showed robust reactivity with the cell surface of neurons. The identity of the antigens was established by immunoprecipitation and mass spectrometry, and subsequently confirmed with cell-based assays, immunohistochemistry with teased rat sciatic nerve, and immunoabsorption experiments.

Results: Four of 46 sera from patients with CIDP reacted strongly against hippocampal neurons (8.6%) and paranodal structures on peripheral nerve. Two patients' sera precipitated contactin-1 (CNTN1), and 1 precipitated both CNTN1 and contactin-associated protein 1 (CASPR1). Reactivity against CNTN1 was confirmed in 2 cases, whereas the third reacted only when CNTN1 and CASPR1 were cotransfected. No other CIDP patient or any of the 104 controls with other neurological diseases tested positive. All 3 patients shared common clinical features, including advanced age, predominantly motor involvement, aggressive symptom onset, early axonal involvement, and poor response to intravenous immunoglobulin.

Interpretation: Antibodies against the CNTN1/CASPR1 complex occur in a subset of patients with CIDP who share common clinical features. The finding of this biomarker may help to explain the symptoms of these patients and the heterogeneous response to therapy in CIDP.

Citing Articles

Inter-Laboratory Validation of Nodal/Paranodal Antibody Testing.

Lleixa C, Titulaer M, Rohrbacher S, Mgbachi V, Halstead S, Fehmi J J Peripher Nerv Syst. 2025; 30(1):e70000.

PMID: 39887819 PMC: 11780190. DOI: 10.1111/jns.70000.


Conformational Antibodies to Proteolipid Protein-1 and Its Peripheral Isoform DM20 in Patients With CNS Autoimmune Demyelinating Disorders.

Masciocchi S, Businaro P, Greco G, Scaranzin S, Malvaso A, Morandi C Neurol Neuroimmunol Neuroinflamm. 2025; 12(2):e200359.

PMID: 39823554 PMC: 11744608. DOI: 10.1212/NXI.0000000000200359.


The Discovery of Autoimmune Nodopathies and the Impact of IgG4 Antibodies in Autoimmune Neurology.

Querol L, Dalakas M Neurol Neuroimmunol Neuroinflamm. 2024; 12(1):e200365.

PMID: 39671536 PMC: 11649181. DOI: 10.1212/NXI.0000000000200365.


Chronic Immune Sensory Polyradiculopathy (CISP): A Systematic Review of the Literature.

Singhal S, Khanna R, Surendranath A, Chhabra J, Thakkar V, Gupta R Neurol Int. 2024; 16(6):1214-1222.

PMID: 39585051 PMC: 11586984. DOI: 10.3390/neurolint16060092.


Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice.

Loser V, Vicino A, Theaudin M Front Neurol. 2024; 15:1495205.

PMID: 39555481 PMC: 11565704. DOI: 10.3389/fneur.2024.1495205.